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3-iodothyroacetic acid (TA1), an end metabolite of thyroid hormone, has been shown
to produce behavioral effects in mice that are dependent on brain histamine. We now
aim to verify whether pharmacologically administered TA1 has brain bioavailability and is
able to induce histamine-dependent antidepressant-like behaviors. TA1 brain, liver and
plasma levels were measured by LC/MS-MS in male CD1 mice, sacrificed 15 min after
receiving a high TA1 dose (330 µgkg−1). The hypothalamic mTOR/AKT/GSK-β cascade
activation was evaluated in mice treated with 0.4, 1.32, 4 µgkg−1 TA1 by Western-blot.
Mast cells were visualized by immuno-histochemistry in brain slices obtained from
mice treated with 4 µgkg−1 TA1. Histamine release triggered by TA1 (20–1000 nM)
was also evaluated in mouse peritoneal mast cells. After receiving TA1 (1.32, 4 or
11 µgkg−1; i.p.) CD1 male mice were subjected to the forced swim (FST) and the
tail suspension tests (TST). Spontaneous locomotor and exploratory activities, motor
incoordination, and anxiolytic or anxiogenic effects, were evaluated. Parallel behavioral
tests were also carried out in mice that, prior to receiving TA1, were pre-treated with
pyrilamine (10 mgkg−1; PYR) or zolantidine (5 mgkg−1; ZOL), histamine type 1 and
type 2 receptor antagonists, respectively, or with p-chloro-phenylalanine (100 mgkg−1;
PCPA), an inhibitor of serotonin synthesis. TA1 given i.p. to mice rapidly distributes in the
brain, activates the hypothalamic mTOR/AKT and GSK-3β cascade and triggers mast
cells degranulation. Furthermore, TA1 induces antidepressant effects and stimulates
locomotion with a mechanism that appears to depend on the histaminergic system.
TA1 antidepressant effect depends on brain histamine, thus highlighting a relationship
between the immune system, brain inflammation and the thyroid.
Keywords: 3-iodothyroacetic acid, thyroid hormone, histamine, mast cells, antidepressant effect
Abbreviations: BBB, blood brain barrier; FST, forced swim test; H1R, type 1 histamine receptor; H2R, type 2 histamine
receptor; PCPA, p-chloro-phenylalanine; PYR, pyrilamine; T1AM, 3-iodothyronamine; TA1, 3-iodothyroacetic acid; TST,
tail suspension test; ZOL, zolantidine.
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INTRODUCTION
Recent evidence indicates that thyroid hormone metabolism
may generate compounds endowed of behavioral and
metabolic effects.
The TA1 is the last iodinated thyroacetic acid produced
by sequential metabolism of thyroid hormone carried out by
deiodinases and amine oxidases activities. While little is still
known about the TA1 tissue levels and their physiological
significance, the pharmacological effects of TA1 have been
extensively studied. In this respect, we have described that the
systemic administration of low TA1 doses (µgkg−1) induced
central and peripheral effects. The central effects that were
reported include the activation of neuronal signaling, such as
the pro-survival PI3K/AKT cascade (Laurino et al., 2018b), the
stimulation of memory and reversion of scopolamine-induced
amnesia (Musilli et al., 2014; Laurino et al., 2015a), the
stimulation of wakefulness in mice prone to sleep for a high
acute dose of ethanol (Laurino et al., 2018a). In addition, recent
data indicate that TA1 may behave as a potent anticonvulsant
and neuroprotective agent against excitotoxicity (Laurino et al.,
2018b). Among peripheral effects, TA1 has been reported to
induce itching, along with a reduction of noxious and painful
sensitivity (Laurino et al., 2015b). Common determinants of TA1
central and peripheral effects are their rapid onset (within 15 min
of administration), the fact that they were described by typical
inverted U-shaped dose-effect curves, and their dependence on
the activation of the histaminergic system. Such behavioral effects
indicate that TA1 may cross the BBB and that histamine might
derive from a site where it is “ready to be released.” However,
direct evidence of brain distribution, as well as the source of
histamine involvement in TA1 behavioral effects remain elusive.
In the brain, histamine is present in the histaminergic
neurons, that are localized in the hypothalamus from where they
project to most of the brain areas, but also in non-neuronal
cells including mast cells, that are multifunctional bone
marrow-derived tissue-dwelling cells and are considered one
of the major sources of histamine in body tissues, including
the brain. Mast cells are mainly localized along the blood
vessels on the brain side of the BBB (Skaper and Fusco, 2014)
and are considered crucial mediators of glial cells-neurons
communication, whose main signaling pathway is represented
by the activation of the PI3K/AKT cascade (Dong et al., 2017).
At the BBB, mast cells represent the first-line of defense against
brain invasion by xenobiotics, quickly releasing pre-stored and
newly synthesized mediators, including histamine, serotonin
and other pro-inflammatory signals (Theoharides and Cochrane,
2004). Despite the low number of mast cells in the healthy
brain, it is estimated they can store up to 50% of the brain
histamine (Yamatodani et al., 1982). Potentially, mast cells
may be a target for TA1. Indeed, recent evidence indicates
that histamine, irrespective of its derivation (neuronal and not
neuronal), is implicated in the regulation of feeding and sleep-
awake cycle (Lin et al., 1986), as well as in the stimulation of
locomotion and emotional behaviors, including modulation of
anxiety and depression (Lamberti et al., 1998; Wada et al., 1991;
Chikahisa et al., 2013).
The aim of the present work is to investigate whether TA1:
(i) has brain bioavailability after systemic administration, (ii) can
trigger histamine release from mast cells and (iii) is endowed of
histamine-dependent antidepressant-like effects in rodents.
MATERIALS AND METHODS
Animals
Male CD1 mice (weight: 20–30 g) purchased from ENVIGO
(Italy) were used in the present study. Five mice were housed per
cage. Cages were placed in the experimental room 24 h prior to
testing to ensure adaptation. Animals were housed at 23 ± 1◦C
under a 12 h light–dark cycle (lights on at 07:00) and were
fed a standard laboratory diet with ad libitum access to water.
Experiments and animal use procedures were in accordance with
the National Institutes of Health Guide for the Care and Use
of Laboratory Animals (NIH Publications No. 80–23, revised
1996). The experimental protocols were approved by the ethical
Committee of the Italian Council of Health, in compliance
with the European Convention for the Protection of Vertebrate
Animals used for Experimental and Other Scientific Purposes
(ETS no. 123) and the European Communities Council Directive
of 24 November 1986 (86/609/EEC). The authors further attest
that all efforts were made to minimize the number of animals
used and their suffering.
For this study we received the permission from the Ethical
Committee for animal health 176/2017-PR) from the Italian
Ministry of Health.
Male CD1 mice (20–30 g) from ENVIGO (Italy) were used.
The animals were kept at 22 ± 1◦C with a 12 h light–dark cycle
(light on at 07:00 h) and were fed a standard laboratory diet with
water ad libitum. Five mice were housed per cage.
Determination of TA1 Brain, Liver and
Plasma Distribution After Systemic
Administration
Twenty male mice were divided in two groups of 10 mice each.
One group received injection i.p. of a saline solution (control
mice), while the other received 330 µgkg−1 TA1 dissolved in
saline solution (Veh) (Laurino et al., 2018a). This dose which
was approximately ten times higher than the doses of TA1 found
active on mice behavior, Was chosen to be sure to detect TA1
levels in the analyzed tissues.
Five mice from each group were sacrificed 15 min after TA1
administration, the remaining mice (five from each group) were
sacrificed after 60 min. At each time point, the blood, the brain
and the liver were removed and quickly frozen until used to
assess the TA levels by liquid chromatography tandem mass
spectrometry (LC/MS-MS). Due to the small amount of plasma
obtained, TA1 determination was carried on a pooled plasma
sample from five control or treated mice (at 15 and 60 min
after treatment).
Assays were performed on plasma (300 µL), brain and
liver samples (130–190 mg). Each sample was placed in a
2 mL Precellys tube, 1 ml of 85:15 (v/v) Acetonitrile/0.1 M
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HCl (aq) solution containing 5 nM internal standard (TA1-D4)
was added, and the sample was sonicated for 30 minutes and then
homogenized using a Precellys 24 beads grinder (2.8 mm ceramic,
zirconium oxide, beads). The homogenate of each sample was
placed in an ultrasound bath (LBS1 3Lt, Falc Instruments,
Treviglio, Italy) for 15 minutes and then centrifuged for 15 min at
1300 × g at room temperature. The residual pellet was discarded
and the supernatant was placed in a new 12 ml glass centrifuge
tube. The solution was subjected to liquid/liquid extraction
with hexane (3 mL ×1 mL). The upper phase (hexane) was
discarded and the lower phase (acetonitrile) was dried under a
gentle stream of nitrogen at 45◦C. Samples were then dissolved
in 100 µL reconstitution solvent mixture (H2O:MeOH, 70:30)
and analyzed using LC-MS/MS to assess TA1 concentration as
described elsewhere (Saba et al., 2010).
In vivo Mast Cells Staining
CD1 mice were treated intraperitoneally with Veh or 4 µgkg−1
TA1. After 15 min from injection, animals were sacrificed by
CO2 inhalation and brains were collected and fixed for 24 h
in Mota fluid (1% lead acetate in 49.57% Absolute ethanol
49.75% Water and 0.5% Acetic acid), dehydrated in graded
ethanol and embedded in paraffin. The presence of mast cells
and their content in secretion granules were highlighted by
both conventional histological staining and histochemistry. In
particular, 5 µm thick histological coronal sections collected at
the hippocampus level, were stained with Astra blue (Fluka,
Buchs, Switzerland). This cationic dye binds specifically to
heparin contained in the mast cell granules (Cinci et al., 2010).
Mast cells were histochemically labeled with FITC conjugated
avidin (1:400; Sigma Aldrich, Milan, Italy). Avidin is able to
electrostatically bind with high sensitivity to mast cell granules
(Bacci et al., 2014).
Mice Peritoneal Mast Cells Isolation and
Culture: The Effect of TA1 on Histamine
Release
Mast cells were isolated from peritoneum of CD1 mice as
described in Meurer et al. (Meurer et al., 2016). Briefly, a small
incision below the sternum of the animal was performed without
puncturing the peritoneum. 10 ml of ice cold sterile PBS were
injected in the peritoneal cavity and a soft massage of about 30 s
was performed. Cell suspension was centrifuged at 4◦C at 300× g
for 10 min, re-suspended in 5 ml of PBS and then centrifuged
again at 4◦C at 300 × g for 10 min. Cells were suspended in
RPMI medium and incubated at 37◦C and 5% CO2. After 3 days,
not adherent cells were removed and fresh culture medium was
added. After 6 days, 5 ml of fresh medium were added and at day
10 mast cells (represented by the non-adherent population) were
harvested and used for experiments.
Mast cells were plated in 12 well plate (about 25000 cells/well)
and treated with vehicle (PBS) alone, 5 mg/ml Apis mellifera
venom (ENTOMON s.a.s Florence, Italy, gently gifted by Prof.
Stefano Turillazzi and prepared in vehicle) or 20 nM, 100 nM,
and 1 µM of TA1. Culture media were harvested after 5, 15, 30,
60, 90, and 120 min after treatment. Histamine was measured
by the method described in Tiligada et al. (2000) with some
modifications. Briefly, 50 µl of each sample was incubated with
12.5 µl of 0.44 M of NaOH+ 0.1% O-phthaldialdehyde (Sigma
Aldrich, Milan, Italy) for 10 min at RT. Then the reaction was
stopped by adding 12.5µl of 0.5 M HCl and fluorescence was read
by a microplate reader (360 nm excitation and 450 nm emission).
Results for each treatment were expressed as baseline-corrected
(Veh) fluorescence.
Vehicle or 1 µM TA1 treated cells were placed on a slide
after 15 min of treatment and stained with Astra blue to visualize
histamine content.
Determination of Signaling Activity of
TA1 at Hypothalamus
Twelve male CD1 mice were randomly divided in 4 groups of 3
mice each. One group received i.p. Veh the other mice received
0.4 or 1.32 or 4 µgkg−1 TA1. Mice were sacrificed 15 min
after administration to remove the hypothalamus. The tissue was
frozen at−80◦C until used for western-blot analysis.
Western Blot
Proteins (20 µg) isolated from mouse hypothalamus were
separated via 4–20% SDS-PAGE and transferred into PVDF
membranes (60 min at 398 mA) using standard procedures.
Blots were incubated overnight at 4◦C with specific antibodies
against p- AKT S473, AKT, p-GSK-3β S9, GSK-3β, p-mTOR
S2448 and mTOR (Cell Signaling Technology, Denver, MA,
United States) and GAPDH (Merk-Millipore, Darmstadt,
Germany). Primary antibodies were diluted in PBS containing
1% albumin or 5% non-fat dry milk and 0.05% Tween. The
antigen–antibody complexes were visualized using appropriate
secondary antibodies (1:10 000, diluted in PBS containing 1%
albumin or 5% non-fat dry milk and 0.05% Tween) and incubated
for 1 h at room temperature. Blots were then extensively washed
with PBS containing 0.1% Tween and developed using an
enhanced chemiluminescence detection system (Pierce, Rodano,
Italy). Exposition and developing time were standardized for all
blots. Densitometric analysis of scanned images was performed
on a Macintosh iMac computer using the public domain NIH
Image J program. Results are presented as the mean ± SEM of
different gels and expressed as arbitrary units (AU), which depict
the ratio between levels of target phosphorylated protein and the
total protein expression normalized to basal levels.
BEHAVIORAL STUDIES
Treatments
Mice were randomized to receive i.p., administration of saline
solution (Veh), or 1.32 or 4 µgkg−1 TA1 dissolved in Veh
(Laurino et al., 2018a). Experiments were also performed in
mice pre-treated i.p. with Veh or with antagonists of type 1 and
type 2 histamine receptors, i.e., pyrilamine (10 mgkg−1; PYR,
prepared in Veh) and zolantidine (5 mgkg−1 i.p.; ZOL, prepared
in Veh), 20 min before they received 4µgkg−1 TA1 or Veh. When
p-chloro-phenylalanine (100 mgkg−1; PCPA), the inhibitor of the
Frontiers in Cellular Neuroscience | www.frontiersin.org 3 May 2019 | Volume 13 | Article 176
fncel-13-00176 May 7, 2019 Time: 15:30 # 4
Laurino et al. Brain Histamine and the 3-Iodothyroacetic Acid
tryptophan hydroxylase activity was used 4 µgkg−1 TA1 or Veh,
were administered to mice which had received a daily injection
of PCPA for 4 days. TA1 or Veh were administered 1 h after the
last PCPA injection. All drugs were administered at a volume of
10 mlkg−1 body weight.
Mouse behavior was observed 15 min after TA1
administration according to the specific methods listed below.
The Hole Board-Platform
The hole-board test was performed according to (Romanelli
et al., 2006). The experimental setting consisted of a 40 cm
square plane with 16 flush mounted cylindrical holes (3 cm
diameter), distributed four by four in an equidistant, grid-like
manner. Mice were placed in the center of the board one by one
and allowed to move about freely for a period of 5 min. Two
electric eyes, crossing the plane from midpoint to midpoint of the
opposite sides, thus dividing the plane into four equal quadrants,
automatically signaled mouse movements (locomotor activity).
Miniature photoelectric cells in each of the 16 holes recorded hole
exploration. Animal groups consisted of 10 mice and were tested
10 min after the injections.
The Rota-Road Test
The integrity of the animals’ motor coordination was assessed
using a rota-rod apparatus at a rotating speed of 24 rpm. The
numbers of falls from the rod in 30 s, 15 min after drug
administration were counted.
The Forced Swimming Test (FST)
The test was conducted as described by Porsolt et al. (1977). Mice
(10 animals/group) were individually forced to swim in an open
cylindrical container (diameter 10 cm, height 25 cm), containing
19 cm of water at 25 ± 1◦C. In the test, the time of immobility
was measured during a 6-min period. A decrease in the duration
of immobility is indicative of an antidepressant effect.
The Tail Suspension Test (TST)
A piece of tape was adhered to the upper middle of the tail of
each animal, creating a flap with the overlap of tape. Mice were
suspended from a plastic rod mounted 50 cm above the surface
by fastening the tail to the rod with adhesive tape. The duration
of the test was 6 min. Immobility was defined as the absence of
any limb or body movements, except those caused by respiration.
The Light Dark Box
The light–dark box was made of white and black opaque
apparatus (length 50 cm, width 20.5 cm, and height 19 cm)
consisted of two equal acrylic compartments, one dark and
one white, illuminated by a 60-W bulb lamp and separated
by a divider with a 10 cm × 3.2 cm opening at floor level.
Each mouse was placed in the middle of the light chamber
facing a side away from the door and then released. Mice’
behaviors were scored for 300 s and included the latency
to the first step into the dark compartment, the duration of
time spent in the light chamber, the number of full-body
transitions between chambers. These behaviors have previously
been measured as a reflection of anxiety in this apparatus
(Bourin and Hascoët, 2003). After testing, subjects were
removed from the light–dark box and returned to their home
cage in colony room. The apparatus was cleaned with 70%
ethanol after each use and allowed to dry before the next
subject was tested.
Statistical Analysis
Data are expressed as mean ± SEM of independent experiments.
Statistical analysis was performed by the One or Two way
ANOVA test followed by Tukey or Dunnett or Bonferroni
Multiple Comparison Test. The threshold of statistical
significance was set at P < 0.05. Data analysis was performed
using the GraphPad Prism 5.0 statistical program (GraphPad
software, San Diego, CA, United States).
RESULTS
Endogenous and Pharmacological
Tissue Levels of TA1
3-iodothyroacetic acid endogenous or pharmacological
tissue levels were measured by liquid chromatography
tandem mass spectrometry (LC-MS/MS) in mice sacrificed
15 min after treatment with Veh or with 330 µgkg−1 TA1
(Chiellini et al., 2012).
In Veh-treated mice, we were unable to measure TA1
endogenous levels in the brain and in the pooled plasma sample,
whereas TA1 was detected in liver (Table 1).
In TA1-treated mice, 15 min after pharmacological
administration, TA1 was recovered in the pooled plasma sample
(19% of the dose administered), in the brain and in the liver
of all the mice treated (1.3 and 32% of the dose administered,
respectively). In the liver, pharmacological administration
produced a 165-fold increase of TA1 level (ng/g) when compared
to endogenous levels.
As expected, TA1 tissue levels reduced with time. After 60 min
from TA1 administration, plasma and liver levels decreased
in parallel resulting approximately ten times lower than those
measured at 15 min. In the brain, TA1 levels at 60 min were
only four times lower than those measured at 15 min. These
results suggest that tissues have different TA1 clearance capacity,
TABLE 1 | 3-iodothyroacetic acid (TA1) levels in mice following intra-peritoneal




Saline N.D. N.D. 0.64 ± 0.2
TA1 (15 min) 63.7a 4.2 ± 1 106 ± 22
19%◦◦ 1.3% 32%
TA1 (60 min) 9.4a 1.1 ± 0.3 10.47 ± 0.45
2.8% 0.33% 3.17%
afrom pooled blood samples. ◦◦The percentage of TA1 recovered in respect of the
administered dose (330 µgkg-1).
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with the brain conserving TA1 levels for longer than plasma or
liver (Table 1).
TA1 Degranulates Brain Mast Cells
We then investigated whether treatment with 4 µgkg−1 TA1 was
associated with brain mast cells degranulation.
Our results indicated that, at our staining conditions, i.e.,
both avidin and Astra Blue, very few mast cells were detectable
in the brain. Although the low number of mast cells could be
considered as a sign of the extreme specificity of our staining
protocols, we could also not exclude that the method of tissue
fixation may not allow the retention of mast cells granular content
in the central portion of the brain (Figure 1A). These technical
considerations/limitations notwithstanding, we were still able to
highlight differences in mast cell granular content between the
two experimental groups (Figures 1B–E).
In fact, in Veh-treated mice, the mast cells detected showed
substantially intact granular content (Figures 1B,D). Instead, in
brain slices prepared from mice treated with 4 µgkg−1 TA1, the
few mast cells that were stained showed reduced granular content
(Figures 1C,E).
TA1 Releases Histamine From Peritoneal
Mast Cells
To confirm the capacity of TA1 to trigger histamine release from
mast cells, we performed in vitro experiments exposing isolated
mouse peritoneal mast cells to increasing concentrations of TA1.
Our results indicated that TA1 effectively degranulated
peritoneal mast cells (Figures 2A,B). In fact, histamine levels
in cell medium significantly increased (compared to Veh) when
mast cells were exposed to increasing TA1 concentrations
(Figure 2A) or to bee venom (BV) and mast cells appear
degranulated (Figure 2B).
In particular, the Two-way ANOVA test indicated that, at
the concentrations tested, TA1 significantly increased histamine
release at all the times of cell exposure without a clear
concentration dependent effect on the time of exposure. Kinetic
data indicated that the releasing capacity of the acid showed
a trend to increase from 5 to 15 min of cell exposure and
then it remained almost stable up to 30 min (Figure 2A)
indicating granular histamine depauperation in the absence of a
fast re-synthesis.
TA1 Activates the Hypothalamic
AKT/mTOR and Reduces the GSK-3β
Activity
Since kinetic data indicated the presence of TA1 in the brain of
mice 15 min after administration, we investigated whether TA1
was able to activate any signaling activity when administered at
the pharmacological doses previously found to induce behavioral
effects (Laurino et al., 2018a). For this aim, mice were sacrificed
15 min after treatment with 4 µgkg−1 TA1 or vehicle (Veh) and
the hypothalamus was isolated.
Our results showed that the treatment with TA1 produced
activation of the AKT/p-mTOR/GSK-3β cascade depending on
the dose administered. In fact, while p-GSK-3β levels resulted
significantly increased in the hypothalamus of mice that received
1.32 and 4 µgkg−1 TA1 (Figures 3A,C; ∗P < 0.05 vs. Veh), the
levels of p-AKT and p-mTOR were found increased over Veh
only in those mice treated with 4 µgkg−1 TA1 (Figures 3A–D,
FIGURE 1 | The effect of TA1 on brain mast cell degranulation. Mast cells were stained as described in Methods. (A) Astra blue staining, representative image of a
hemisphere. Few mast cells are visible in the upper portion (black arrows) 35x magnification; scale bar 600 µm. (B,C) Representative images of mast cells exposed
to Veh (picture B) or to 4 µgkg−1 TA1 (C) stained with FITC conjugated avidin (green). (D,E) Representative images of Astra blue stained mast cells exposed to Veh
(D) or to 4 µgkg−1 TA1 (E). 1000× magnification; scale bar 100 µm.
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FIGURE 2 | TA1 releases histamine from peritoneal mast cells. Peritoneal mast cells were prepared and exposed to 20, 100, or 1000 nM TA1 as described in
Methods. (A) Histamine accumulation was evaluated by fluorescence in cell medium after 5, 15, 30 min of cell exposure to TA1 or to Apis mellifera venom (BV; 5
mgml−1). Results are expressed as means ± SEM of three different experiments run in duplicate (∗P < 0.05, ∗∗P < 0.01 and ∗∗∗P < 0.001 vs. Veh.). (B) Picture 1:
mast cells stained with Astra Blue following 15 min exposure to Veh. A representative image is showed. Picture 2: representative image of mast cells stained with
Astra Blue following 15 min exposure to 1 µM TA1.
One-way ANOVA test followed by Tukey post hoc test;
∗P < 0.05 vs. Veh).
TA1 TREATMENT INDUCES
ANTIDEPRESSANT-LIKE EFFECTS
TA1 Reduces the Immobility Time in
the FST
The FST is a validated methodological tool for pre-clinical
assessment of antidepressant drug activity. In this test, the
behavioral immobility of the mice represents a condition of
“despair,” since the mice give up moving after realizing that escape
is impossible. Consistently, we performed the FST to investigate
the possible antidepressant effects of TA1.
One-way ANOVA analysis of the data obtained from the
FST indicated that 4 and 11 µgkg−1 TA1 significantly reduced
the immobility time (∗∗P < 0.01 and ∗∗∗P < 0.001 vs. Veh.
respectively and ◦P < 0.05 vs. 1.32 µgkg−1 TA1 post hoc
Tukey Multiple Comparison Test), thus supporting a possible
antidepressant effect of TA1, which required to be confirmed by
additional tests (Figure 4A).
TA1 Reduces the Immobility Time in
the TST
The TST is a test based on the assumption that the animal will
try to escape the stressful situation (i.e., mice suspended). After
a certain time, the animal ceases to struggle and immobility
occurs. As for the FST, longer immobility times are sign of
depressive behavior.
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FIGURE 3 | The effects of TA1 on hypothalamic p-PI3K/AKT and p GSK-3 levels. Male CD1 mice received an intraperitoneal injection of either vehicle (Veh) or 0.4,
1.32 and 4 µgkg−1 TA1. Hypothalamic levels of p-AKT (B), p-GSK-3β (C), and p-mTOR (D) were assessed 15 min after mice treatment. (A) A representative
experiment is shown. (B–D) Densitometric analysis is showed. Results are presented as the mean ± SEM of 3 different experiments; ∗P < 0.05 vs. Veh. (One-way
ANOVA test followed by Tukey Multiple Comparison Test).
Mice were subjected to the TST in order to confirm the results
obtained in the FST. Results showed that 4 and 11 µgkg−1 TA1
treatment significantly reduced the immobility time in the TST
too (∗P < 0.05 and ∗∗P < 0.01 vs. Veh treated mice; Figure 4B).
The Antidepressant Effect of TA1
Includes the Activation of the
Histaminergic System
As previously reported, the behavioral effects induced by TA1
resulted to be mediated by the activation of the histaminergic
system, since these actions are modulated by anti-histaminergic
drugs (Laurino et al., 2015a, 2017a,b). In line with this evidence,
we aimed to investigate whether the antidepressant effects of TA1
were also modulated by treatment with anti-histaminergic drugs
(i.e., PYR and ZOL).
As a control, the treatment of mice with ZOL and PYR alone
did not affect the immobility time of mice in both FST and TST
tests in respect of Vehicle (Veh) treated mice (One-way Anova
test followed by Tukey Multiple Comparison test Figures 4C–E).
In mice pre-treated with 10 mgkg−1 PYR, TA1, at all the
doses tested, failed to reduce the immobility time of the mice
(Figure 4C). Instead, in mice pre-treated with 5 mgkg−1 ZOL, 4
and 11 µgkg−1 TA1 significantly reduced the immobility time in
the FST (∗P < 0.05 and ∗∗P < 0.01 vs. Veh alone respectively,
###P < 0.001 and ##P < 0.01 vs. ZOL respectively, Tukey
Multiple Comparison Test analysis) (Figure 4D).
Consistently, in the TST, in mice pre-treated with 10 mgkg−1
PYR, TA1 4 and 11 µgkg−1 did not induce any significantly
reduction of the immobility time of the mice (Figure 4E).
The Antidepressant Effect of TA1 Does
Not Include the Serotoninergic System
To investigate the involvement of serotonin in TA1
antidepressant effects, we performed the FST on mice deprived
of serotonin after a 4 day treatment with PCPA, an inhibitor of
the tryptophan hydroxylase activity.
Our results showed that mice treated for 4 days
with 100 mgkg−1 PCPA had immobility time similar
to Veh-treated mice (Figure 4F, One-Way Anova test
followed by Tukey Multiple Comparison test). At this
condition, the administration of 4 and 11 µgkg−1 TA1 still
significantly reduced the immobility time vs. Veh-treated
mice (Figure 4F; ∗P < 0.05 and ∗∗∗P < 0.001 vs. Veh,
###P < 0.001 vs. PCPA, ◦◦◦P < 0.01 vs. 1.32 µgkg−1 TA1,
Tukey Multiple Comparison Test). These data indicated
that the serotoninergic system was not involved in TA1
antidepressant effect.
TA1 Does Not Show Anxiolytic-Like
Effects
The antidepressant effect of drugs might derive from their
anxiolytic features. To exclude that TA1 was endowed of
anxiolytic effects we performed the light-dark box test with mice
which received 4 and 11 µgkg−1 TA1. The One-way Anova test
of results followed by Dunnett’s post hoc test indicated that mice
treated with TA1 and Veh spent a similar amount of time in
the light (Figure 5A), in the dark compartments (Figure 5B)
and had a similar number of transitions from light to dark
compartments (Figure 5C).
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FIGURE 4 | The effect of 3-iodothyroacetic acid (TA1) treatment on the immobility time in the forced swim test (FST) and in the tail suspension test (TST): evidence
for the involvement of histamine and not of serotonin. Mice received 1.32, 4 and 11 µgkg−1 TA1 and after 15 min they were subjected to the FST (A) or to TST (B).
The immobility time was measured as described in Methods. (A) The immobility time measured in mice subjected to the FST is reported. Results are the
means ± SEM of three different experiments were at least ten mice were used (∗∗P < 0.01 and ∗∗∗P < 0.001 vs. Veh and ◦P < 0.05 vs. 1.32 µgkg−1 TA1; One-way
ANOVA test followed by Tukey Multiple Comparison Test). (B) Immobility time measured in mice subjected to the TST is reported. Results are the means ± SEM of
three different experiments using at least ten mice (∗P < 0.05 and ∗∗P < 0.01 vs. Veh; One-way ANOVA test followed by Tukey Multiple Comparison Test). (C,D) The
FST was then repeated in mice pre-treated with Vehicle (Veh) or with pyrilamine (10 mgkg−1; PYR; C) or with zolantidine (5 mgkg−1, ZOL; D) before receiving 4 or
11 µgkg−1 TA1 as described in Methods. The Immobility time was measured. Results are the means ± SEM of three different experiments were at least ten mice
were used (∗P < 0.05 and ∗∗P < 0.01 vs. Veh; ###P < 0.001 and ##P < 0.01 vs. ZOL, One-way ANOVA test followed by Tukey Multiple Comparison Test ); (E) The
TST was repeated in mice pre-treated with pyrilamine (10 mgkg−1; PYR) before receiving 4 and 11 µgkg−1 TA1 as described in Methods. The Immobility time was
measured. Results are the means ± SEM of three different experiments were at least ten mice were used (One-way ANOVA test followed by Tukey Multiple
Comparison Test); (F) the FST was repeated in mice pre-treated for 4 days with p-chloro methyltyrosine (100 mgkg−1; PCPA) and then with 1.32, 4 and 11 µgkg−1
TA1 as described in Methods. The Immobility time was measured. Results are the means ± SEM of three different experiments were at least ten mice were used
(∗P < 0.05 and ∗∗∗P < 0.001 vs. Veh, ###P < 0.001 vs. PCPA, ◦◦P < 0.01 vs. 1.32 µgkg−1; One-way ANOVA test followed by Tukey Multiple Comparison Test).
TA1 Increases Mouse Spontaneous
Locomotor Activity: Evidence for
Histamine Involvement
The hole-board test is a validated model for evaluating the
spontaneous locomotor activity and exploratory behavior of
animals in a new environment (File, 1973).
Mice were put on the hole board platform 15 min after
receiving 1.32, 4 and 11 µgkg−1 TA1 or Veh to measure the effect
of the treatment on their locomotor and exploratory activities,
i.e., curiosity (Figures 6A,B).
One-Way ANOVA analysis of the results indicated that only
4 µgkg−1 TA1 treatment, and not 1.32 or 11 µgkg−1, induced
a significant increase of mice locomotor activity (∗∗P < 0.01
vs. Veh treated mice). On the other hand, any of the TA1
doses administered modified the mice exploratory activity
(curiosity) (Figure 6B).
Mice receiving PYR and ZOL showed locomotor activity
similar to Veh-treated mice (Figures 6C,D, One-way
Anova test followed by Tukey Multiple Comparison
Test). We next verified whether TA1 stimulation
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FIGURE 5 | TA1 does not show anxyolitic-like effects. The light dark paradigm was carried on mice received 1.32, 4 and 11 µgkg−1 TA1 or vehicle (Veh) as
described in Methods. Results are expressed as the means ± SEM of measurements relative to 10 mice. Mice behaviors were scored for 300 sec and included (A)
the duration of time spent in the light chamber, (B) the latency to the first step into the dark compartment, (C) the number of full-body transitions between chambers.
of mice locomotion was modified in mice treated
with PYR and ZOL.
In mice treated with PYR, 4 µgkg−1 TA1 conserved its
capacity to stimulate mice locomotor activity (∗P < 0.05 vs. Veh,
#p< 0.05 vs. PYR, Tukey Multiple Comparison Test, Figure 6C),
while in ZOL pre-treated mice, 4 µgkg−1 TA1 significantly
reduced mice locomotor activity (∗∗P < 0.01 vs. Veh, #P < 0.05
vs. ZOL; Tukey’s Multiple Comparison Test, Figure 6D).
PYR (10 mgkg−1), but not ZOL-treatment, induced per se
reduction of mice exploratory activity (curiosity) (∗P < 0.05
vs. Veh, Tukey’s Multiple Comparison Test; Figures 6E,F).
Interestingly, in these mice, the administration of 4 µgkg−1 TA1
reverted PYR-induced depression of mice curiosity (Figure 6E;
#P < 0.05 vs. PYR,). Instead, 4 µgkg−1 TA1 did not affect the
curiosity of mice pre-treated with ZOL (Figure 6F).
TA1 Does Not Produce Motor
Incoordination
Mice receiving 4 and 11 µgkg−1 TA1 i.p. were then put on the
accelerated rota-road as described in “Methods.” In these settings,
mice treated with TA1 or with Veh showed similar performances
with respect to the number of falls (data not shown), thus
suggesting that TA1 did not compromise motor coordination.
DISCUSSION
We here demonstrate that TA1 shows brain bioavailability
after systemic administration. The presence of TA1 in the
brain is associated with the activation of the hypothalamic
AKT and GSK-3β signaling pathways and the induction of
emotional effects, including antidepressant-like effects. This
result is independent on modulation of anxiety but it is
associated with a mild stimulation of mice locomotion. Overall,
these results demonstrate that TA1 is able to cross the BBB,
a site where TA1 could activate mast cell degranulation.
Indeed, TA1 systemic administration is associated with mast
cell degranulation, and in vitro evidence demonstrates that
TA1 may trigger histamine release from peritoneal mast cells.
Interestingly, TA1 antidepressant-like effects and the stimulation
of mice locomotion are modulated by anti-histaminergic drugs,
thus confirming the dependence of these effects on the release of
histamine. Even though the source of histamine involved in such
Frontiers in Cellular Neuroscience | www.frontiersin.org 9 May 2019 | Volume 13 | Article 176
fncel-13-00176 May 7, 2019 Time: 15:30 # 10
Laurino et al. Brain Histamine and the 3-Iodothyroacetic Acid
FIGURE 6 | TA1 increases mouse spontaneous locomotor activity: evidence for histamine involvement. Mice were put on the hole board 15 min after 1.32, 4, and
11 µgkg−1 TA1 administration to evaluate the effect of the treatments on spontaneous locomotor activity and exploratory activities. Results are expressed as the
means ± SEM of measurements relative to 10 mice. (A,B) The effect of TA1 treatment on spontaneous mice locomotion (A) and exploratory activity (curiosity, B) is
showed (∗∗P < 0.01 vs. One-way ANOVA test followed by Tukey Multiple Comparison Test). (C,D) Mice locomotion was evaluated in mice pre-treated i.p. with Veh
or with pyrilamine (10 mgkg−1; PYR; C) or with zolantidine (5 mgkg−1; ZOL; D),before receiving 4 µgkg−1 TA1 or Veh as described in Methods. Results are the
means ± SEM of measures relative to 10 mice (∗P < 0.05 and ∗∗P < 0.01 vs. Veh, #P < 0.05 vs. PYR/ZOL, One-was ANOVA test followed by Tukey Multiple
Comparison Test). (E,F) Mice curiosity (exploratory activity) was evaluated in mice pre-treated with Veh or with PYR (E) or ZOL (F) before receiving 4 µgkg−1 TA1 or
Veh. (∗P < 0.05 and #P < 0.05 vs. PYR, One-way ANOVA test followed by Tukey Multiple Comparison Test).
effects (and in general with all the behavioral effects observed
after administering TA1) remains elusive, our results provide
further insight into the mechanism of TA1 action, suggesting that
mast cells are a possible source of the histamine responsible for
TA1 central-mediated behavioral effects.
TA1 is considered a by-product of thyroid hormone
metabolism, produced by at least two independent synthetic
pathways. However, little is known about the pattern of
tissue distribution of endogenous and/or pharmacologically
administered TA1. This issue has limited the exploration of the
possible pathogenic or diagnostic role of this thyroid hormone
metabolite in thyroid diseases. Our present results indicate that
the endogenous levels of TA1 in mice brain and plasma are
undetectable at our settings, whereas endogenous TA1 is highly
detectable in liver. As expected, TA1 tissue levels increased
following pharmacological administration. In particular, TA1
brain and plasma levels became detectable just 15 min after
systemic administration, and, at this time point, a significant
increase was also observed in liver as compared to control
mice. These data provide evidence that TA1 is able to cross the
BBB, and confirm that the liver is a preferential site not only
of thyroid hormone but also of thyroid hormone metabolites
accumulation (Porsolt et al., 1977; Saba et al., 2010). In line
with this, our data also indicate that TA1 liver levels do not
derive exclusively from local synthesis. Another interesting aspect
of TA1 pharmacokinetic, is the different kinetic of tissue level
reduction. Our data show that 60 min after administration, the
decrease of TA1 brain levels was less than liver and plasma
levels, suggesting that TA1 brain clearance might be lower than
that of the liver. Moreover, even though the amount of TA1
recovered in the brain is only a small percentage of the dose
administered, the brain may represent a site of “preservation of
low levels” of TA1. These data are consistent with our previous
observations (Laurino et al., 2015b) and suggest TA1 brain levels
may be homeostatically controlled. However, the mechanism
used by TA1 to cross the BBB and liver membranes remains to
be investigated. Whichever mechanism is adopted, the passage
of TA1 across the BBB implies an interaction with the cells
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lying on the brain side of the barrier, including mast cells,
and the distribution in brain areas, including the hypothalamus
where histaminergic neurons are highly concentrated. As a novel
finding, our data demonstrate that TA1 has the capacity to
degranulate mast cells and to trigger histamine release from
peritoneal mast cells, showing a maximum effectiveness at 15 min
after cell exposure and a minimum TA1 effective concentration
of 20 nM. Notably, this concentration is in the range of the
pharmacological doses of TA1 administered to mice, and the
time of 15 min is also in line with the activation of the
hypothalamic signals and the onset of the behavioral effects
here described. Interestingly, the accumulation of histamine in
cell medium did not depend linearly on the concentration of
TA1. In fact, at 1 µM TA1, the histamine medium content
did not increase further with respect to the amount released
by 20 and 100 nM TA1, thus indicating a fast release of
histamine in the absence of re-synthesis. The absence of a linear
concentration-dependent effect might also explain the U-shaped
dose-effect curves described for the in vivo effects of TA1 reported
in literature. To note, mast cells express all the four subtypes of
histamine receptors (Csaba et al., 2007) and can store thyroid
hormone (Harvima et al., 2014). Overall, the fact that TA1, a
thyroid hormone metabolite, may trigger histamine release from
mast cells reinforces the hypothesis of a dual relationship between
the endocrine, including the thyroid, and the immune system, a
relationship which might have interesting clinical implications.
15 min after TA1 administration, an intracellular
hypothalamic signaling is found to be activated. In particular,
a 4 µgkg−1 TA1 dosage results in the activation of the AKT
which is among the targets of mast cells-derived histamine
(Kim et al., 2018), but it is also the cascade activated in the
enhancement of cognition and the neuroprotection offered
by type 3 histamine receptor antagonists/inverse agonists,
whose effects are mainly due to the disinhibition of neuronal
histamine release (Bitner et al., 2011; Bhowmik et al., 2014). At
the same doses that are effective on signaling activation, TA1
induces antidepressant-like effects. As already observed in the
case of pro-cognitive properties, these effects are prevented by
pre-treating mice with an H1R antagonist (Lamberti et al., 1998).
In addition, our results demonstrate that the antidepressant effect
of TA1 is not a consequence of an anxiolytic effect and it is
unrelated to serotonin, the amine co-stored with histamine in
mast cells and strongly interplaying with neuronal histamine
in the control of mood tone (Munari et al., 2015). Instead,
we found that TA1 stimulates mice movements on the plane
without giving motor incoordination. As for the antidepressant-
like effects, mice locomotor activity results modulated by
antihistaminergic drug treatment revealing a main role for the
H2R activation. Interestingly, TA1 was also found to stimulate
mice curiosity when the H1R is blocked, a condition which
depresses, per se, mice curiosity. This finding highlights the role
of TA1 in stimulating curiosity even when this is particularly
depressed, a condition mimicking depression, and reinforces
the involvement of the histaminergic system in TA1 behavioral
effects. All the effects here described were observed in a the same
narrow range of doses previously reported to stimulate memory
(Laurino et al., 2015a; Bellusci et al., 2017), wakefulness (Laurino
et al., 2018a), to protect neuron from excitotoxicity, to reduce
PZT-induced seizures (Laurino et al., 2018b). Overall, these
behavioral effects indicate that TA1 is a mild psychostimulant
which, interestingly, rapidly increases the level of attention, the
mood tone and cognition capacity of the subject without inducing
motor incoordination.
In conclusion, our findings indicate that TA1 is a potent
antidepressant-like drug displaying a rapid onset of action
whose mechanism appears to involve brain histamine. Our
data suggest that histamine may derive, at least in part, from
brain mast cells. The observation that TA1 triggers histamine
release from mast cells opens the way to the existence of
a novel and not-yet-explored relationship between thyroid
endocrine components, anxiety like behaviors and the immune
system (Landucci et al., 2019). In addition, since mast cells are
ubiquitous cells, the degranulating capacity of TA1 has to be
taken into consideration when the pharmacological effects of TA1
are investigated.
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